Dual Oral Anti-Diabetic Formulation
Drglim - M2
Glimepiride 2mg + Metformin HCl 500mg (SR)
Synergistic combination targeting both pancreatic insulin secretion and peripheral insulin resistance for long-term target HbA1c maintenance.
Standardized Actives
Glimepiride IP 2mg + Metformin Hydrochloride IP 500mg (Sustained Release).
Therapeutic Purpose
- Type 2 Diabetes Mellitus glycemic management where monotherapy is insufficient
- Fasting hyperglycemia and insulin resistance mitigation
- Cardiometabolic risk reduction in overweight diabetic cohorts
Administration & Care
1 tablet once daily with the main morning or evening meal.
Strip of 10 tablets in moisture-barrier blister. — Store below 25°C. Protect from direct heat and light.
Quality, Safety & Manufacturing Standards
Every batch of Aanav Healthcare formulations is manufactured under strict current Good Manufacturing Practices (cGMP) in licensed facilities in Mumbai, India. We subject all active pharmaceutical ingredients and botanical extracts to multi-stage purity, stability, and assay tests.
- Product Title
- Drglim - M2 (Glimepiride 2mg + Metformin HCl 500mg (SR))
- Therapeutic Segment
- Dual Oral Anti-Diabetic Formulation — Diabetology
- Active Formula
- Glimepiride IP 2mg + Metformin Hydrochloride IP 500mg (Sustained Release).
- Dosage & Use
- 1 tablet once daily with the main morning or evening meal.
- Pack Packaging
- Strip of 10 tablets in moisture-barrier blister.
- Storage Guidelines
- Store below 25°C. Protect from direct heat and light.
- Regulatory Compliance
- Schedule H Prescription Drug — cGMP Certified.
Other Formulations in Diabetology
Oral Hypoglycemic Sulfonylurea
Shortepa - 1
Second-generation sulfonylurea formulation that stimulates pancreatic beta-cell insulin secretion with lower risk of severe hypoglycemia for Type 2 diabetes management.
Oral Hypoglycemic Sulfonylurea
Shortepa - 2
Advanced 2mg Glimepiride formulation providing 24-hour glycemic control for diabetic patients requiring enhanced pancreatic insulin secretory support.
DPP-4 Inhibitor & Biguanide Combination
Tinashe
Fixed-dose combination of a potent, selective DPP-4 inhibitor and sustained-release metformin for comprehensive 24-hour glycemic control without weight gain.